BUZZ-Merck jumps as lab demand lifts 2026 outlook

Merck

Merck

MRK

0.00

** Germany's Merck MRCG.DE is up 4.4% in early Frankfurt trade after it raised its full-year guidance on stronger demand for its lab supplies and delayed competition for its Mavenclad multiple sclerosis drug

** The science and healthcare firm also reported higher-than-expected Q1 EBITDA of 1.53 billion euros, beating average analyst expectations of 1.46 billion euros

** "Given the strong set of results and FY’26 Guidance upgrade... we expect the shares to outperform by 2-3% today," JPMorgan says

** The stock is at the top of German blue-chip index DAX .GDAXI in early Frankfurt trade


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.